Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Recruitment Messages for Current Smokers Recently Diagnosed With Cancer

20 de julio de 2022 actualizado por: University of Oklahoma

A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial

The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer. To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures. We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.

Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.

Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.

Tipo de estudio

Intervencionista

Inscripción (Actual)

99

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Estados Unidos
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Jordan Neil

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Speak and understand English
  • A recent cancer diagnosis (within the past 24 months)
  • 18 years or older
  • Report any cigarette use within the past 30 days

Exclusion Criteria:

  • Do not speak or understand English
  • Have not been diagnosed with cancer within the past 24 months
  • Below the age of 18
  • Does not report any cigarette use within the past 30 days

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador falso: Control
The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
Conductual: Control
Does not include any of the three message factors.
Experimental: Proximal x Cost x Loss
Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
Conductual: Proximal
The first factor tested framing of the near, proximal threat of continued smoking.
Conductual: Cost
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
Conductual: Loss
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Experimental: Proximal x Cost x Gain
Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
Conductual: Proximal
The first factor tested framing of the near, proximal threat of continued smoking.
Conductual: Cost
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
Conductual: Gain
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Experimental: Proximal x Benefit x Gain
Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
Conductual: Proximal
The first factor tested framing of the near, proximal threat of continued smoking.
Conductual: Gain
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Conductual: Benefit
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
Experimental: Proximal x Benefit x Loss
Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
Conductual: Proximal
The first factor tested framing of the near, proximal threat of continued smoking.
Conductual: Loss
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Conductual: Benefit
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
Experimental: Distal x Cost x Gain
Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
Conductual: Cost
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
Conductual: Gain
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Conductual: Distal
The first factor tested framing of the long-term, distal threat of continued smoking.
Experimental: Distal x Cost x Loss
Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
Conductual: Cost
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
Conductual: Loss
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Conductual: Distal
The first factor tested framing of the long-term, distal threat of continued smoking.
Experimental: Distal x Benefit x Loss
Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
Conductual: Loss
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Conductual: Benefit
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
Conductual: Distal
The first factor tested framing of the long-term, distal threat of continued smoking.
Experimental: Distal x Benefit x Gain
Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
Conductual: Gain
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Conductual: Benefit
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
Conductual: Distal
The first factor tested framing of the long-term, distal threat of continued smoking.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in intent to talk to a physician about participating in a smoking cessation study between factors.
Periodo de tiempo: Within 30 minutes
The main effect within each message factor level was examined using ANOVA and compared with the control condition.
Within 30 minutes

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Predictors of intent to talk to a physician about participating in a smoking cessation study.
Periodo de tiempo: Within 30 minutes
Other message evaluation and effectiveness measures were collected and explored in a multivariable model predicting intent to talk to a physician.
Within 30 minutes

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

University of Oklahoma

Colaboradores

Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Tufts University

Investigadores

  • Investigador principal: Jordan Neil, Ph.D., TSET Health Promotion Research Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de febrero de 2019

Finalización primaria (Actual)

1 de abril de 2019

Finalización del estudio (Actual)

2 de abril de 2019

Fechas de registro del estudio

Enviado por primera vez

13 de julio de 2022

Primero enviado que cumplió con los criterios de control de calidad

20 de julio de 2022

Publicado por primera vez (Actual)

22 de julio de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de julio de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

20 de julio de 2022

Última verificación

1 de julio de 2022

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 2018P002035

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Control

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Bahamas

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

3
Suscribir